Drug updated on 3/28/2024
| Dosage Form | Tablet (oral; 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1000 mcg, 1200 mcg, 1400 mcg, 1600 mcg); Injection (Intravenous; 1800 mcg) |
| Drug Class | Prostacyclin receptor agonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.
Summary
- Selexipag (Uptravi) is used for the treatment of pulmonary arterial hypertension (PAH, WHO Group I), aiming to delay disease progression and reduce the risk of hospitalization.
- A systematic review and meta-analysis found that selexipag significantly improved hospitalization rates due to worsening PH, World Health Organization Functional Class (WHO FC), mean Pulmonary Arterial Pressure (mPAP), NT-proBNP levels, and cardiac index in patients with PH.
- In a comparison study between riociguat and selexipag for PAH treatment, an indirect treatment comparison showed comparable efficacy between both drugs; however, riociguat was identified as cost-saving therapy compared to selexipag.
- Another analysis revealed that oral administration of prostacyclin mimetics like selexipag demonstrated less clinical worsening without discernable impact on survival but increased adverse events such as vasodilation, headache, jaw pain among others when compared with placebo or other treatments.
- The value contribution assessment conducted in Spain through reflective Multicriteria Decision Analysis methodology indicated that oral administration of Selexipag provides significant value addition over inhaled iloprost by improving patient-reported outcomes while maintaining similar safety profiles despite higher acquisition costs than iloprost.
- Based on seven Systematic Reviews / Meta-Analyses documents reviewed about Uptravi's effectiveness against PAH conditions; it has been concluded that vardenafil combined with bosentan shows relatively better performance regarding both efficacy and safety aspects among all targeted drug therapies available currently for treating PAH conditions including Selexipage (Uptravi).
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Uptravi (selexipag) Prescribing Information. | 2022 | Actelion Pharmaceuticals US, Inc., South San Francisco, CA |